Hyperlactatemia and Elective Tumor Craniotomy: Prospective Observational Study of Prevalence, Risk Factors, and Association With Short-Term Outcomes

BACKGROUND: Hyperlactatemia is common during brain tumor craniotomy, although the pathophysiology and association to outcome are unclear. We prospectively investigated prevalence and risk factors for perioperative hyperlactatemia (S-lactate ≥2.2 mM) as well as its association with short-term outcomes in patients undergoing elective brain tumor craniotomy. METHODS: In 450 patients, arterial lactate was measured hourly from the first surgical incision until 6 hours postoperatively. The primary outcome was a change in the level of neurological disability, measured by the modified Rankin Scale preoperatively and at 30 days after surgery. Secondary outcomes were length of hospital stay, new neurological deficits at discharge, days alive and out of hospital at 30 days, and 30-day mortality. Hyperlactatemia was analyzed both as a dichotomous (≥1 measurement of S-lactate ≥2.2 mM) and as a continuous variable (lactate load). We used both a multivariable regression and a backward stepwise regression analysis to identify risk factors for hyperlactatemia and factors associated with postoperative outcomes. RESULTS: Hyperlactatemia was seen in 66% of the study participants. No association was found between hyperlactatemia and modified Rankin Scale change from baseline to 30 days or any other clinical outcome. Independent factors associated with hyperlactatemia were mean perioperative glucose (0.14; 95% CI: 0.09-0.18; P<0.001), preoperative glucocorticoid dose (0.09; 95% CI: 0.06-0.12, P<0.001), malignant CNS-derived tumor type (0.25; 95% CI: 0.08-0.42; P=0.004), and inverse noradrenaline dose (-0.02; 95% CI: -0.04 to -0.006, P=0.006). CONCLUSIONS: We did not find an association between perioperative hyperlactatemia and short-term outcomes in patients undergoing brain tumor craniotomy. Preoperative glucocorticoids, perioperative glucose, malignant CNS tumor, and noradrenaline dose were independently associated with hyperlactatemia.

Authors

Institutions

Publication Details

Journal
Journal of Neurosurgical Anesthesiology
Published
2026-05-22
DOI
https://doi.org/10.1097/ana.0000000000001090
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hyperlactatemia and Elective Tumor Craniotomy: Prospective Observational Study of Prevalence, Risk Factors, and Association With Short-Term Outcomes

Christine Sølling, Alexandra Vassilieva, Kirsten Møller, Ingrid L. Granerud et al.
Journal of Neurosurgical Anesthesiology
Glioma Diagnosis and Treatment
article

Hyperlactatemia and Elective Tumor Craniotomy: Prospective Observational Study of Prevalence, Risk Factors, and Association With Short-Term Outcomes

Christine Sølling, Alexandra Vassilieva, Kirsten Møller, Ingrid L. Granerud, Martin K. Sørensen, Markus H. Olsen, CONICA, Jane Skjøth-Rasmussen
article en

Abstract

BACKGROUND: Hyperlactatemia is common during brain tumor craniotomy, although the pathophysiology and association to outcome are unclear. We prospectively investigated prevalence and risk factors for perioperative hyperlactatemia (S-lactate ≥2.2 mM) as well as its association with short-term outcomes in patients undergoing elective brain tumor craniotomy. METHODS: In 450 patients, arterial lactate was measured hourly from the first surgical incision until 6 hours postoperatively. The primary outcome was a change in the level of neurological disability, measured by the modified Rankin Scale preoperatively and at 30 days after surgery. Secondary outcomes were length of hospital stay, new neurological deficits at discharge, days alive and out of hospital at 30 days, and 30-day mortality. Hyperlactatemia was analyzed both as a dichotomous (≥1 measurement of S-lactate ≥2.2 mM) and as a continuous variable (lactate load). We used both a multivariable regression and a backward stepwise regression analysis to identify risk factors for hyperlactatemia and factors associated with postoperative outcomes. RESULTS: Hyperlactatemia was seen in 66% of the study participants. No association was found between hyperlactatemia and modified Rankin Scale change from baseline to 30 days or any other clinical outcome. Independent factors associated with hyperlactatemia were mean perioperative glucose (0.14; 95% CI: 0.09-0.18; P<0.001), preoperative glucocorticoid dose (0.09; 95% CI: 0.06-0.12, P<0.001), malignant CNS-derived tumor type (0.25; 95% CI: 0.08-0.42; P=0.004), and inverse noradrenaline dose (-0.02; 95% CI: -0.04 to -0.006, P=0.006). CONCLUSIONS: We did not find an association between perioperative hyperlactatemia and short-term outcomes in patients undergoing brain tumor craniotomy. Preoperative glucocorticoids, perioperative glucose, malignant CNS tumor, and noradrenaline dose were independently associated with hyperlactatemia.

Journal of Neurosurgical Anesthesiology
Twitter (United States) (US), University of Copenhagen (DK), Copenhagen University Hospital (DK), Rigshospitalet (DK), Neural Signals (United States) (US), Danish Working Environment Authority (DK)
Good health and well-being
Openalex Percentile: Top 6%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.